Glycomet Trio 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake by muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance. Glycomet Trio 2 is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy, providing a multifaceted approach to glycemic management by targeting different pathophysiological mechanisms of diabetes. It is essential to monitor blood glucose levels regularly and adjust dosages based on therapeutic response and tolerance. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis or type 1 diabetes. Common side effects may include gastrointestinal disturbances, hypoglycemia, and mild allergic reactions. This combination therapy should be used under medical supervision to optimize efficacy and safety.